Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/1996
06/11/1996US5525613 Covalently coupled benzoylecgonine ecgonine and ecgonidine
06/11/1996US5525606 Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
06/11/1996US5525604 4-aminopyrimidine derivatives
06/11/1996US5525600 Compound useful as antipsychotic, antidepressant and anxiblytic agents
06/11/1996US5525593 Used for regeneration of muscle tissue, minimizing scar formation during healing of wound
06/11/1996US5525354 Salts of dichloromethylene bisphosphonic acid in drug delivery form with acid-dissolving enteric coating, for oral administration
06/06/1996WO1996017070A1 Method of preparing a viral vector by homologous intermolecular recombination
06/06/1996WO1996017057A1 Sox-9 gene and protein and use in the regeneration of bone or cartilage
06/06/1996WO1996016981A2 Peptide compounds for prevention and/or treatment of no-mediated diseases
06/06/1996WO1996016970A1 Substituted 2-(phosphinyloxymethyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
06/06/1996WO1996016964A1 Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
06/06/1996WO1996016961A1 (thiophen-2-yl)-piperidin or tetrahydropyridin carboxamides
06/06/1996WO1996016960A1 Quinazoline derivatives
06/06/1996WO1996016955A1 Processes and intermediates for preparing cis(+)3-[4,-6-dihydroxychroman-3-ylmethyl]-4-methoxyaniline
06/06/1996WO1996016952A1 2-substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
06/06/1996WO1996016951A1 Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives and compositions and method of use thereof
06/06/1996WO1996016949A1 Novel 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives, their preparation and use as drugs
06/06/1996WO1996016939A1 Perhydroisoindole derivatives as antagonists of substance p
06/06/1996WO1996016931A1 Metalloproteinase inhibitors
06/06/1996WO1996016666A1 Method for the specific immunoadsorption of selected pathogenic factors
06/06/1996WO1996016665A1 Cd40 associated proteins
06/06/1996WO1996016657A1 Bicyclic heterocyclic compounds for the treatment of impotence
06/06/1996WO1996016654A1 2-(2,3,5,6-tetrafluoro-4-pyridyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
06/06/1996WO1996016653A1 Immunorejection inhibitor
06/06/1996WO1996016652A2 Use of rifabutin and a combination of rifabutin and atovaquone in the treatment of pneumocystis carinii infections
06/06/1996WO1996016649A1 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
06/06/1996WO1996016646A1 Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
06/06/1996WO1996016644A1 cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION
06/06/1996WO1996016642A1 Matrix type patch preparation
06/06/1996WO1996016632A1 Cosmetic or pharmaceutical compositions containing mangiferin or derivatives thereof
06/06/1996WO1996016542A1 Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5)
06/06/1996WO1995032298A3 Safe vectors for gene therapy
06/06/1996CA2206441A1 Cd40 associated proteins
06/06/1996CA2206422A1 Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
06/06/1996CA2206305A1 Sox-9 gene and protein and use in the regeneration of bone or cartilage
06/06/1996CA2206303A1 Matrix type patch formulation
06/06/1996CA2205972A1 Metalloproteinase inhibitors
06/06/1996CA2205970A1 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
06/06/1996CA2205950A1 Substituted 2-(phosphinyloxymethyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
06/06/1996CA2205837A1 Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives and compositions and method of use thereof
06/06/1996CA2205800A1 2-(2,3,5,6-tetrafluoro-4-pyridyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
06/06/1996CA2205799A1 2-substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
06/06/1996CA2205584A1 (thiophen-2-yl)-piperidin or tetrahydropyridin carboxamides
06/06/1996CA2180745A1 Cosmetic or pharmaceutical compositions containing mangiferin or derivatives thereof
06/06/1996CA2164375A1 Heterocyclic amides
06/05/1996EP0714907A1 Oligoribonucleotides with amide backbone
06/05/1996EP0714903A1 New carbohydrate conjugates as cell adhesion inhibitors
06/05/1996EP0714896A1 Indol derivatives useful for the treatment of migraine, composition and utilization
06/05/1996EP0714894A1 3-(1,2,3,6-tetrahydro-(1-alkylenearyl)-4-pyridinyl)- and 3-(1-alkylenearyl)-4-piperidinyl-1h-indoles: new 5-HT1f agonists
06/05/1996EP0714883A1 Aryloxypropanolamine beta 3 adrenergic agonists
06/05/1996EP0714665A2 Osteogenic devices
06/05/1996EP0714663A2 Potentiation of drug response by a serotonin 1A receptor antagonist
06/05/1996EP0714660A1 Ranolazine and related piperazines for protecting skeletal muscles
06/05/1996EP0714449A1 Oligonucleotide modulation of protein kinase c
06/05/1996EP0714418A1 Cosmetic melanins
06/05/1996EP0714408A1 Tryptase inhibitor
06/05/1996EP0714397A1 Phenethylamine compounds
06/05/1996EP0714392A1 Heterocycles useful as neurokinin antagonists
06/05/1996EP0714391A1 Substituted 2(5h)furanone, 2(5h)thiophenone and 2(5h)pyrrolone derivatives, their preparation and their use as endothelin antagonists
06/05/1996EP0714390A1 Indole derivatives as 5-alpha-reductase-1-inhibitors
06/05/1996EP0714389A1 Amide and urea derivatives as 5ht1d receptor antagonists
06/05/1996EP0714308A1 Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
06/05/1996EP0714299A1 Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
06/05/1996EP0714294A1 Pharmaceutical compositions comprising metal complexes
06/05/1996EP0714293A1 3-cyano-3-(3,4-disubstituted)phenylcyclohexyl-1-carboxylates
06/05/1996EP0714291A1 Lupane triterpenoid derivatives
06/05/1996EP0714290A1 Compositions and methods for the detection and treatment of protein trafficking disorders and increasing secretory protein production
06/05/1996EP0714284A1 Use of oligosaccharides for the prevention and treatment of tissue ageing
06/05/1996EP0569383B1 LOW-MOLECULAR SULPHATED POLY-$g(b)-2,6-FRUCTOFURANOSANES AND THEIR USE IN THE TREATMENT OF DEGENERATIVE ARTICULAR AILMENTS
06/05/1996CN1031940C Process for preparing substituted pyrrole compounds
06/04/1996US5523475 2-nitro-3-hydroxybenzoic acids as enzyme inhibitors of 3-hydroxyanthranilate oxygenase active in producing the neurotoxin, quinolinic acid
06/04/1996US5523457 Used for preventing or treating skin disorders like acne, psoriasis, damage for irradiation; antitumor agent
06/04/1996US5523456 Anticarcinogenic agents
06/04/1996US5523455 Prepared using a naphthylhydrazine chemical intermediate
06/04/1996US5523407 Quinoline derivatives, their production and use as ACAT inhibitors
06/04/1996US5523319 Compounds of the benzo-heterocycle family
06/04/1996US5523315 N-(hydroxyethyl)butanediamide derivatives
06/04/1996US5523308 Peptidyl heterocycles useful in the treatment of thrombin related disorders
06/04/1996US5523094 Aqueous mixture of alfuzosin, organic solvent and absorption promoter
06/04/1996EP0722440A4 Pyrimidinyl-glutamic acid derivatives
06/03/1996CA2164246A1 Aryloxypropanolamine beta 3 adrenergic agonists
06/02/1996CA2161209A1 3-<1,2,3,6-tetrahydro-<1-alkylenearyl>-4-pyridinyl>- and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-ht1f agonists
05/1996
05/31/1996CA2163392A1 Oligoribonucleotides with amide backbone
05/30/1996WO1996016176A1 FUSION PROTEINS WITH CYTOTOXIC ACTIVITY AGAINST CELLS OVEREXPRESSING erbB3 AND/OR erbB4
05/30/1996WO1996016175A2 Lgmd gene coding for a calcium dependent protease
05/30/1996WO1996016173A2 Modified proteinase inhibitors
05/30/1996WO1996016170A2 Proteins involved in the regulation of cell-cell adhesion and uses thereof
05/30/1996WO1996016088A1 Protein affecting katp channels
05/30/1996WO1996016087A1 G-protein coupled receptor
05/30/1996WO1996016084A2 A method of identifying cftr-binding compounds useful for activating chloride conductance in animal cells
05/30/1996WO1996016080A1 Human neutrophil elastase inhibitors
05/30/1996WO1996016058A1 Aminomethyl aryl compounds; dopamine receptor subtype selective ligands
05/30/1996WO1996016056A1 Piperazine, piperidine & tetrahydropyridine derivatives useful as 5-ht1 receptor agonists
05/30/1996WO1996016049A1 OXAZOLE DERIVATIVES AS ANTAGONISTS OF α-1C ADRENERGIC RECEPTORS
05/30/1996WO1996016040A1 Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
05/30/1996WO1996016036A1 18-nor-vitamin d compounds
05/30/1996WO1996016035A1 18,19-dinor-vitamin d compounds
05/30/1996WO1996016027A1 Matrix metalloprotease inhibitors
05/30/1996WO1996015797A1 Pharmaceutical compositions comprising nitric oxide-releasing biopolymers
05/30/1996WO1996015795A1 Compositions containing lazaroids and their use for preventing adhesions
1 ... 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 ... 1564